Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
83.61
+0.57 (+0.69%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gilead Sciences
< Previous
1
2
3
4
5
6
7
8
9
...
50
51
Next >
If You Invested $100 In This Stock 20 Years Ago, You Would Have $900 Today
April 17, 2024
Via
Benzinga
Why the dividend investor may take a look at NASDAQ:GILD.
April 17, 2024
Uncovering Dividend Opportunities with GILEAD SCIENCES INC (NASDAQ:GILD).
Via
Chartmill
Better Growth Play: Merck or The Vanguard Growth Index Fund?
April 15, 2024
Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund?
Via
The Motley Fool
Should You Buy the 3 Highest-Paying Dividend Stocks in the Nasdaq?
April 15, 2024
Dividend stocks can be a smart way to ride out market volatility.
Via
The Motley Fool
Biotech Innovations Paving the Way in Breast Cancer Fight
April 11, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:GTHX),(NASDAQ:AZN),(NASDAQ:HOLX) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Product Safety
If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,000 Today
April 03, 2024
Via
Benzinga
Analyzing NASDAQ:GILD's Dividend Potential.
March 26, 2024
Is GILEAD SCIENCES INC (NASDAQ:GILD) a Good Fit for Dividend Investing?
Via
Chartmill
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter
April 11, 2024
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
3 Stocks at 52-Week Lows Poised for a Powerful Rebound
April 09, 2024
Starbucks, Gilead, and Vale are three stocks at 52-week lows that show signs of recovery potential and long-term growth prospects.
Via
InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
April 09, 2024
Via
Benzinga
Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024
April 08, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Starbucks, Gilead And Ambev Are At 52-Week Lows: Should You Buy The Dip?
April 08, 2024
Capital market investors often look for entry points, hidden gems, and value bets. Quality stocks trading at or around their 52-week low levels offer one such opportunity window.
Via
Benzinga
3 No-Brainer Dividend Stocks to Buy in April
April 06, 2024
Income investors will find a lot to like about these stocks.
Via
The Motley Fool
Got $5,000? These 3 High-Yielding Dividend Stocks Are Trading Near Their 52-Week Lows
April 05, 2024
All of these stocks pay generous dividends that income investors will appreciate.
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
April 03, 2024
Via
Benzinga
Biotech Sector Nears Breakout: Will it Outperform in Q2?
April 03, 2024
The Biotech sector ETF is consolidating in its upper range, indicating a potential sector breakout despite modest year-to-date gains
Via
MarketBeat
Topics
ETFs
5 Healthcare Stocks to Buy for 2024
April 02, 2024
Healthcare stocks have been some of the top performers in 2024, and thanks to the potential of AI, these names will just keep heating up.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: Analyst
April 01, 2024
BofA Securities downgrades Galapagos to underperform due to limited near-term catalysts and competitive challenges in crowded markets.
Via
Benzinga
10 Big-Name Stocks Near 52 Week Lows: Are They A Buy?
March 29, 2024
Over the past twelve months, a number of big-name companies have been near or below their 52-week low price. Each week we’ll take a look at some of the biggest names currently close to their 52-week...
Via
Talk Markets
Cancer Focused Micro-Cap Xilio Therapeutics Stock Doubles In One Session - Here's Why
March 28, 2024
Xilio Therapeutics soars with exclusive license pact with Gilead Sciences to advance XTX301, a Phase 1 tumor-activated IL-12 program. $43.5 million upfront, $604 million potential payments, and tiered...
Via
Benzinga
Why Is Xilio Therapeutics (XLO) Stock up 168% Today?
March 28, 2024
Xilio Therapeutics stock is heading higher on Thursday with heavy trading of XLO shares after announcing a deal with Gilead.
Via
InvestorPlace
FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
March 28, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
March 28, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
March 28, 2024
From
Xilio Therapeutics, Inc.; Gilead Sciences, Inc.
Via
GlobeNewswire
7 Value Stocks to Buy at a 52-Week Low in March
March 28, 2024
These seven value stocks to buy all trade at low valuations, and have the potential to make big recoveries.
Via
InvestorPlace
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
March 27, 2024
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Via
Benzinga
Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
March 25, 2024
Some of the market’s favorite biotech stocks have created immense wealth, as evidenced with the recent weight-loss drug stock boom.
Via
InvestorPlace
2 Top Dividend Stocks to Buy Hand Over Fist
March 17, 2024
Every company faces headwinds eventually. The top ones know how to bounce back.
Via
The Motley Fool
10 Big-Name Stocks Near 52-Week Lows: Are They A Buy?
March 16, 2024
Over the past twelve months a number of big named companies have been near or below their 52 week low price. Each week we’ll take a look at some of the biggest names currently close to their 52 week...
Via
Talk Markets
Gilead's Aggressive Push Beyond HIV Treatments - Plans To Increase Cancer-Focused CAR-T Treatment Production
March 15, 2024
Gilead Sciences plans to quadruple cell therapy cancer treatment production by 2026. With a focus on CAR-T treatments like Yescarta and Tecartus, Gilead aims to diversify into oncology. Anticipating a...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
50
51
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.